Kayaking woman.

Nothing less than the opportunity to reach for their treatment goals

For your patients, that’s everything.

Durable, Rapid & Clear

In Ps, most patients achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including response 4 weeks after 1st dose. Most patients who achieved PASI 90 at Week 16 maintained it at Week 52. PASI 100 was achieved by many patients at Week 16 and by a majority at Week 52.1-3

VIEW Ps EFFICACY

Powerful Joint Symptom Relief

In PsA, a majority of patients achieved the primary endpoint of ACR20 at Week 24, experiencing improvement in joint symptoms including patient-reported pain data.1

VIEW PsA EFFICACY

4 Injections a Year

Reliable quarterly dosing after 2 initiation doses at
Weeks 0 and 4 (150 mg/dose) for Ps and PsA.1

VIEW DOSING

PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PASI 100=100% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of clear or almost clear.

Skyrizi single-dose pen.

THE ONLY 4-DOSE-A-YEAR BIOLOGIC FOR PSORIASIS AND FOR PSORIATIC ARTHRITIS THAT OFFERS A SINGLE-DOSE PEN1

FIND OUT MORE
SKYRIZI® is the #1 prescribed biologic in new and switching plaque psoriasis patients.

 

*As of 10/2021. New patients defined as bio-naïve; switch patients defined as bio-experienced switching biologics. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP) through proprietary method on diagnosis classification.

99%

PREFERRED† COMMERCIAL COVERAGE
FOR PATIENTS WITH Ps5

VIEW ACCESS

†Preferred means the product is placed on the plan’s preferred formulary tier. Preferred products may also require a step edit depending on the product’s label. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier.

Skyrizi® (risankizumab-rzaa) Logo.

SKYRIZI HEAD-TO-HEAD DATA VS 3 AGENTS IN DIFFERENT BIOLOGIC CLASSES

Man in a blue swimsuit jumps into a lake

COSENTYX® (secukinumab)6‡

SEE DATA
Woman in a blue dress raises her hands in celebration towards her friends

STELARA®
(ustekinumab)1,2§

SEE DATA
Woman in blue top overlooking a lake

HUMIRA®
(adalimumab)7

SEE DATA
Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See

Full Prescribing Information

‡SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab are not publicly available.8

§ACTIVE COMPARATOR: The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.

At week 161,2: 75% of Skyrizi patients (n=220/294) achieved pasi 90 in the UltIMMa-2 study vs 2% of placebo patients (n=2/98);

84% of SKYRIZI patients achieved sPGA 0/1 vs 5% of placebo patients

UltlMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA
Man folding arms.
Woman in blue swimsuit Woman in blue swimsuit Woman in blue swimsuit

WATCH VIDEO:

SEE THE POSSIBILITIES WITH SKYRIZI
Woman folding arms.

At week 521,2: 81% of Skyrizi patients (n=237/294) achieved pasi 90 in the UltIMMa-2 study; placebo did not continue beyond Week 16

UltlMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=249/304), placebo n/a

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA

Explore
Long-term data

SKYRIZI has long-term efficacy data in Ps
(~5 years) and PsA (~2 years), and long-term safety data (~8 years in Ps, ~3 years in PsA)9-11

Ps EFFICACY
PsA EFFICACY
SAFETY
Woman folding arms.

4 doses
per year1

3-month dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

VIEW DOSING SCHEDULE

FOR BIOCOORDINATORS & OFFICE STAFF

Complete Pro is a flexible and easy-to-use portal designed to streamline and manage the prescription process so patients can start and stay on track with their prescribed treatment.

LEARN MORE ABOUT COMPLETE PRO
Man standing.

NOW HAS PREFERRED|| COVERAGE
FOR 99% OF COMMERCIAL Ps PATIENTS5

 
Skyrizi® Complete Logo.

Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI

VIEW SKYRIZI COMPLETE

National commercial health plan formulary status under the pharmacy benefit updated as of August 2022.5

||Preferred means the product is placed on the plan’s preferred formulary tier. Preferred products may also require a step edit depending on the product’s label. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier. Based on formulary status under the pharmacy benefit.